Therapeutic use of erythropoietin in dermatooncology.
Erythropoietin has been successfully used in Europe since 1997 in the treatment of anemia induced by chemotherapy of solid tumors. There is only limited experience with regard to its use when treating dermatologic tumors such as metastatic melanoma. We review here current guidelines on the use of erythropoietin in cancer patients and report on our own melanoma patients treated with erythropoietin for chemotherapy-induced anemia.
Satzger
Imke
I
Department of Dermatology and Venereology, Skin Tumor Center, Hannover Medical School, Hannover, Germany. satzger.imke@mh-hannover.de
Schenck
Florian
F
Thol
Felicitas
F
Ganser
Arnold
A
Kapp
Alexander
A
Gutzmer
Ralf
R
D000740:Anemia / Q000139:chemically induced* / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003880:Dermatology / Q000379:methods / Q000592:standards / Q000639:trends; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D008495:Medical Oncology / Q000379:methods / Q000592:standards / Q000639:trends; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000639:trends; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy
D000970:Antineoplastic Agents; D004921:Erythropoietin